CN119136796A - 靶向神经降压素受体的化合物和放射性配体及其用途 - Google Patents
靶向神经降压素受体的化合物和放射性配体及其用途 Download PDFInfo
- Publication number
- CN119136796A CN119136796A CN202380034728.3A CN202380034728A CN119136796A CN 119136796 A CN119136796 A CN 119136796A CN 202380034728 A CN202380034728 A CN 202380034728A CN 119136796 A CN119136796 A CN 119136796A
- Authority
- CN
- China
- Prior art keywords
- alkylene
- compound
- alkyl
- groups
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311621P | 2022-02-18 | 2022-02-18 | |
| US63/311621 | 2022-02-18 | ||
| PCT/US2023/013314 WO2023158802A1 (en) | 2022-02-18 | 2023-02-17 | Compounds and radioligands for targeting neurotensin receptor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119136796A true CN119136796A (zh) | 2024-12-13 |
Family
ID=87579080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380034728.3A Pending CN119136796A (zh) | 2022-02-18 | 2023-02-17 | 靶向神经降压素受体的化合物和放射性配体及其用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12145926B2 (https=) |
| EP (1) | EP4479040A1 (https=) |
| JP (1) | JP2025506705A (https=) |
| KR (1) | KR20240150464A (https=) |
| CN (1) | CN119136796A (https=) |
| AU (1) | AU2023221977A1 (https=) |
| CA (1) | CA3243418A1 (https=) |
| CL (1) | CL2024002422A1 (https=) |
| IL (1) | IL314786A (https=) |
| MX (1) | MX2024009858A (https=) |
| WO (1) | WO2023158802A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4479040A1 (en) | 2022-02-18 | 2024-12-25 | Full-Life Technologies HK Limited | Compounds and radioligands for targeting neurotensin receptor and uses thereof |
| WO2025146126A1 (en) * | 2024-01-04 | 2025-07-10 | Full-Life Technologies Hk Limited | Preparation method of compounds targeting neurotensin receptor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| DE4307983A1 (de) | 1993-03-13 | 1994-09-15 | Beiersdorf Ag | Wirkstoffe und kosmetische und dermatologische Zubereitungen |
| FR2732967B1 (fr) * | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| EP2740726A1 (en) * | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| RU2743781C2 (ru) | 2014-06-10 | 2021-02-25 | 3Б Фармасьютикалз Гмбх | Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение |
| EP3279197A1 (en) | 2016-08-03 | 2018-02-07 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnosis, treatment and prevention of neurotensin receptor-related conditions |
| EP4479040A1 (en) | 2022-02-18 | 2024-12-25 | Full-Life Technologies HK Limited | Compounds and radioligands for targeting neurotensin receptor and uses thereof |
-
2023
- 2023-02-17 EP EP23756915.7A patent/EP4479040A1/en active Pending
- 2023-02-17 IL IL314786A patent/IL314786A/en unknown
- 2023-02-17 AU AU2023221977A patent/AU2023221977A1/en active Pending
- 2023-02-17 WO PCT/US2023/013314 patent/WO2023158802A1/en not_active Ceased
- 2023-02-17 JP JP2024548610A patent/JP2025506705A/ja active Pending
- 2023-02-17 KR KR1020247030010A patent/KR20240150464A/ko active Pending
- 2023-02-17 CA CA3243418A patent/CA3243418A1/en active Pending
- 2023-02-17 CN CN202380034728.3A patent/CN119136796A/zh active Pending
-
2024
- 2024-03-13 US US18/604,397 patent/US12145926B2/en active Active
- 2024-08-12 MX MX2024009858A patent/MX2024009858A/es unknown
- 2024-08-13 CL CL2024002422A patent/CL2024002422A1/es unknown
- 2024-09-25 US US18/895,915 patent/US20250026739A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025506705A (ja) | 2025-03-13 |
| EP4479040A1 (en) | 2024-12-25 |
| US12145926B2 (en) | 2024-11-19 |
| US20240287046A1 (en) | 2024-08-29 |
| WO2023158802A1 (en) | 2023-08-24 |
| US20250026739A1 (en) | 2025-01-23 |
| AU2023221977A1 (en) | 2024-08-15 |
| IL314786A (en) | 2024-10-01 |
| CA3243418A1 (en) | 2023-08-24 |
| KR20240150464A (ko) | 2024-10-15 |
| CL2024002422A1 (es) | 2024-12-06 |
| MX2024009858A (es) | 2024-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023201120B2 (en) | FAP inhibitor | |
| TWI657827B (zh) | 用於正子斷層掃描之化合物 | |
| JP2024542592A (ja) | 細胞表面受容体を標的とする開裂可能放射性リガンド及びその使用 | |
| TWI852782B (zh) | 一種成纖維細胞活化蛋白FAP和整合素αvβ3雙重靶向化合物及其製備方法和應用 | |
| US20250026739A1 (en) | Compounds and radioligands for targeting neurotensin receptor and uses thereof | |
| TWI893557B (zh) | 一種靶向sstr2的化合物及其製備方法和應用 | |
| JP2015155407A (ja) | キレート剤 | |
| ES2985919T3 (es) | Agentes diagnósticos y terapéuticos dirigidos a CXCR4 con selectividad de especie reducida | |
| TW200936169A (en) | N-alkoxyamide conjugates as imaging agents | |
| HK40114422A (zh) | 靶向神经降压素受体的化合物和放射性配体及其用途 | |
| RU2838403C1 (ru) | СОЕДИНЕНИЕ ДВОЙНОГО НАЦЕЛИВАНИЯ ДЛЯ БЕЛКА АКТИВАЦИИ ФИБРОБЛАСТОВ (FAP) И ИНТЕГРИНА αvβ3, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ | |
| WO2024083224A1 (en) | Dual receptor targeting radioligands and uses thereof related applications | |
| HK40111230A (zh) | 用於靶向细胞表面受体的可裂解放射性配体及其用途 | |
| WO2026086847A1 (zh) | 环肽偶联药物和应用 | |
| JP2024546710A (ja) | グランザイムｂに特異的な化合物のためのプロドラッグ及びその使用 | |
| CN116375709A (zh) | 一种叶酸受体靶向药物、金属络合物及其制备方法与用途 | |
| HK40127574A (zh) | 放射性药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40114422 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |